BioCryst Pharmaceuticals (BCRX) – Analysts’ Recent Ratings Changes

Posted by Tyrone Williams on Aug 15th, 2024

A number of research firms have changed their ratings and price targets for BioCryst Pharmaceuticals (NASDAQ: BCRX):

8/6/2024 – BioCryst Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
8/6/2024 – BioCryst Pharmaceuticals had its price target raised by analysts at JMP Securities from $15.00 to $16.00. They now have a “market outperform” rating on the stock.
8/6/2024 – BioCryst Pharmaceuticals had its price target raised by analysts at Barclays PLC from $6.00 to $7.00. They now have an “equal weight” rating on the stock.
8/6/2024 – BioCryst Pharmaceuticals was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
8/6/2024 – BioCryst Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX traded up $0.02 during mid-day trading on Thursday, reaching $7.88. The company’s stock had a trading volume of 270,149 shares, compared to its average volume of 3,348,595. The firm has a market capitalization of $1.63 billion, a PE ratio of -7.36 and a beta of 1.88. The stock has a fifty day moving average of $6.89 and a two-hundred day moving average of $5.89. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.09.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.11. The business had revenue of $109.30 million during the quarter, compared to the consensus estimate of $98.30 million. The business’s revenue was up 34.9% on a year-over-year basis. During the same period last year, the company earned ($0.24) EPS. Analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.65 EPS for the current fiscal year.

Insider Activity at BioCryst Pharmaceuticals

In other news, Director Nancy J. Hutson purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was bought at an average cost of $6.38 per share, with a total value of $31,900.00. Following the completion of the purchase, the director now owns 86,818 shares in the company, valued at $553,898.84. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Nancy J. Hutson acquired 5,000 shares of the stock in a transaction dated Monday, May 20th. The stock was acquired at an average cost of $6.38 per share, with a total value of $31,900.00. Following the purchase, the director now directly owns 86,818 shares of the company’s stock, valued at $553,898.84. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Alan G. Levin acquired 7,861 shares of the stock in a transaction dated Thursday, May 30th. The stock was bought at an average cost of $6.36 per share, with a total value of $49,995.96. Following the completion of the purchase, the director now directly owns 44,951 shares in the company, valued at $285,888.36. The disclosure for this purchase can be found here. Over the last three months, insiders bought 15,361 shares of company stock valued at $97,896. Insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently modified their holdings of BCRX. CWM LLC increased its holdings in BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,772 shares during the period. Signaturefd LLC raised its position in shares of BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 5,599 shares in the last quarter. Quarry LP bought a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth $54,000. Seven Eight Capital LP bought a new position in shares of BioCryst Pharmaceuticals in the 1st quarter worth $57,000. Finally, Natixis raised its position in shares of BioCryst Pharmaceuticals by 400.6% in the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 9,350 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.